Overall survival · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to higher overall survival compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
Clinical progression · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to higher clinical progression compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
Treatment failure · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to higher treatment failure compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
Breast pain · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to higher breast pain compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
Gynaecomastia · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to higher gynaecomastia compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
Hot flashes · men with advanced prostate cancer
Non‐steroidal antiandrogen monotherapy probably leads to lower hot flashes compared with LHRH agonists or surgical castration monotherapy (moderate certainty).
1 finding from 1 review
Time to death from any cause (here: overall mortality at 12‐month
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
1 finding from 1 review
Quality of life (Change from baseline to week 15)
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
1 finding from 1 review
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review